Roche: positive phase ii data for Gazyva
(CercleFinance.com) - Roche announces that its Phase II Nobility study, evaluating Gazyva in lupus nephritis patients has achieved its primary endpoint, by showing, in combination with standard of care, superiority over placebo with standard of care.
The Swiss pharmaceutical company states that 40% of patients treated with Gazyva achieved a complete renal response after 76 weeks, compared with 18% of placebo-treated patients. The group plans to start recruiting for a Phase III program.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Swiss pharmaceutical company states that 40% of patients treated with Gazyva achieved a complete renal response after 76 weeks, compared with 18% of placebo-treated patients. The group plans to start recruiting for a Phase III program.
Copyright (c) 2019 CercleFinance.com. All rights reserved.